• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中性粒细胞Shp1的缺失会导致出血性致死性急性肺损伤。

Loss of neutrophil Shp1 produces hemorrhagic and lethal acute lung injury.

作者信息

Moussavi-Harami S F, Cleary S J, Magnen M, Seo Y, Conrad C, English B C, Qiu L, Wang K M, Abram C L, Lowell C A, Looney M R

机构信息

Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco.

Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of California, San Francisco.

出版信息

bioRxiv. 2024 May 28:2024.05.23.595575. doi: 10.1101/2024.05.23.595575.

DOI:10.1101/2024.05.23.595575
PMID:38854059
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11160570/
Abstract

The acute respiratory distress syndrome (ARDS) is associated with significant morbidity and mortality and neutrophils are critical to its pathogenesis. Neutrophil activation is closely regulated by inhibitory tyrosine phosphatases including Src homology region 2 domain containing phosphatase-1 (Shp1). Here, we report that loss of neutrophil Shp1 in mice produced hyperinflammation and lethal pulmonary hemorrhage in sterile inflammation and pathogen-induced models of acute lung injury (ALI) through a Syk kinase-dependent mechanism. We observed large intravascular neutrophil clusters, perivascular inflammation, and excessive neutrophil extracellular traps in neutrophil-specific Shp1 knockout mice suggesting an underlying mechanism for the observed pulmonary hemorrhage. Targeted immunomodulation through the administration of a Shp1 activator (SC43) reduced agonist-induced reactive oxygen species and ameliorated ALI-induced alveolar neutrophilia and NETs . We propose that the pharmacologic activation of Shp1 has the potential to fine-tune neutrophil hyperinflammation that is central to the pathogenesis of ARDS.

摘要

急性呼吸窘迫综合征(ARDS)与显著的发病率和死亡率相关,中性粒细胞对其发病机制至关重要。中性粒细胞的激活受包括含Src同源区2结构域的磷酸酶-1(Shp1)在内的抑制性酪氨酸磷酸酶的密切调控。在此,我们报告,在无菌性炎症和病原体诱导的急性肺损伤(ALI)模型中,小鼠中性粒细胞Shp1缺失通过Syk激酶依赖性机制导致过度炎症和致命性肺出血。我们在中性粒细胞特异性Shp1基因敲除小鼠中观察到大量血管内中性粒细胞聚集、血管周围炎症和过量的中性粒细胞胞外陷阱,提示了观察到的肺出血的潜在机制。通过给予Shp1激活剂(SC43)进行靶向免疫调节可减少激动剂诱导的活性氧,并改善ALI诱导的肺泡中性粒细胞增多和中性粒细胞胞外陷阱形成。我们提出,Shp1的药物激活有可能微调对ARDS发病机制至关重要的中性粒细胞过度炎症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/59abe97b9e0c/nihpp-2024.05.23.595575v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/12e393c2d03f/nihpp-2024.05.23.595575v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/77012482b947/nihpp-2024.05.23.595575v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/3e1ed1238a7d/nihpp-2024.05.23.595575v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/0cfe9cf93a0d/nihpp-2024.05.23.595575v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/87312420ac9c/nihpp-2024.05.23.595575v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/59abe97b9e0c/nihpp-2024.05.23.595575v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/12e393c2d03f/nihpp-2024.05.23.595575v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/77012482b947/nihpp-2024.05.23.595575v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/3e1ed1238a7d/nihpp-2024.05.23.595575v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/0cfe9cf93a0d/nihpp-2024.05.23.595575v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/87312420ac9c/nihpp-2024.05.23.595575v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c9a/11160570/59abe97b9e0c/nihpp-2024.05.23.595575v1-f0006.jpg

相似文献

1
Loss of neutrophil Shp1 produces hemorrhagic and lethal acute lung injury.中性粒细胞Shp1的缺失会导致出血性致死性急性肺损伤。
bioRxiv. 2024 May 28:2024.05.23.595575. doi: 10.1101/2024.05.23.595575.
2
Neutrophil-specific Shp1 loss results in lethal pulmonary hemorrhage in mouse models of acute lung injury.在急性肺损伤小鼠模型中,中性粒细胞特异性的Shp1缺失会导致致命性肺出血。
J Clin Invest. 2024 Oct 1;134(24):e183161. doi: 10.1172/JCI183161.
3
A key role for platelet GPVI in neutrophil recruitment, migration, and NETosis in the early stages of acute lung injury.血小板 GPVI 在急性肺损伤早期中性粒细胞募集、迁移和 NETosis 中起关键作用。
Blood. 2023 Oct 26;142(17):1463-1477. doi: 10.1182/blood.2023019940.
4
Targeting Neutrophils to Prevent Malaria-Associated Acute Lung Injury/Acute Respiratory Distress Syndrome in Mice.靶向中性粒细胞以预防小鼠疟疾相关的急性肺损伤/急性呼吸窘迫综合征
PLoS Pathog. 2016 Dec 7;12(12):e1006054. doi: 10.1371/journal.ppat.1006054. eCollection 2016 Dec.
5
Neutrophil extracellular traps contribute to the pathogenesis of acid-aspiration-induced ALI/ARDS.中性粒细胞胞外诱捕网参与酸吸入诱导的急性肺损伤/急性呼吸窘迫综合征的发病机制。
Oncotarget. 2017 Nov 28;9(2):1772-1784. doi: 10.18632/oncotarget.22744. eCollection 2018 Jan 5.
6
Alpha-linolenic acid pretreatment alleviates NETs-induced alveolar macrophage pyroptosis by inhibiting pyrin inflammasome activation in a mouse model of sepsis-induced ALI/ARDS.α-亚麻酸预处理通过抑制脓毒症诱导的ALI/ARDS 小鼠模型中 pyrin 炎性小体的激活来减轻 NETs 诱导的肺泡巨噬细胞细胞焦亡。
Front Immunol. 2023 Mar 27;14:1146612. doi: 10.3389/fimmu.2023.1146612. eCollection 2023.
7
The link between neutrophils, NETs, and NLRP3 inflammasomes: The dual effect of CD177 and its therapeutic potential in acute respiratory distress syndrome/acute lung injury.中性粒细胞、NETs 和 NLRP3 炎性体之间的联系:CD177 的双重作用及其在急性呼吸窘迫综合征/急性肺损伤中的治疗潜力。
Biomol Biomed. 2024 Jan 13;24(4):798-812. doi: 10.17305/bb.2023.10101.
8
The role of neutrophil extracellular traps in acute lung injury.中性粒细胞胞外诱捕网在急性肺损伤中的作用。
Front Immunol. 2022 Jul 29;13:953195. doi: 10.3389/fimmu.2022.953195. eCollection 2022.
9
Cross-Talk between Shp1 and PIPKIγ Controls Leukocyte Recruitment.Shp1与PIPKIγ之间的相互作用调控白细胞募集。
J Immunol. 2015 Aug 1;195(3):1152-61. doi: 10.4049/jimmunol.1500606. Epub 2015 Jun 22.
10
A novel cell-based assay for dynamically detecting neutrophil extracellular traps-induced lung epithelial injuries.一种用于动态检测中性粒细胞胞外诱捕网诱导的肺上皮细胞损伤的新型细胞检测方法。
Exp Cell Res. 2020 Sep 15;394(2):112101. doi: 10.1016/j.yexcr.2020.112101. Epub 2020 May 29.

本文引用的文献

1
IgG hexamers initiate complement-dependent acute lung injury.IgG 六聚体引发补体依赖性急性肺损伤。
J Clin Invest. 2024 Mar 26;134(11):e178351. doi: 10.1172/JCI178351.
2
Targeting pathogenic macrophages by the application of SHP-1 agonists reduces inflammation and alleviates pulmonary fibrosis.通过应用 SHP-1 激动剂靶向致病性巨噬细胞可减少炎症并缓解肺纤维化。
Cell Death Dis. 2023 Jun 8;14(6):352. doi: 10.1038/s41419-023-05876-z.
3
Mouse-Adapted SARS-CoV-2 MA10 Strain Displays Differential Pulmonary Tropism and Accelerated Viral Replication, Neurodissemination, and Pulmonary Host Responses in K18-hACE2 Mice.
鼠适应的 SARS-CoV-2 MA10 株在 K18-hACE2 小鼠中显示出不同的肺嗜性和加速的病毒复制、神经传播以及肺部宿主反应。
mSphere. 2023 Feb 21;8(1):e0055822. doi: 10.1128/msphere.00558-22. Epub 2023 Feb 2.
4
Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials.巴瑞替尼用于住院COVID-19患者:随机对照试验的荟萃分析
EClinicalMedicine. 2022 Jul;49:101489. doi: 10.1016/j.eclinm.2022.101489. Epub 2022 Jun 3.
5
Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial.福他替尼治疗住院成人 COVID-19:一项随机试验。
Clin Infect Dis. 2022 Aug 24;75(1):e491-e498. doi: 10.1093/cid/ciab732.
6
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.托珠单抗用于治疗新冠肺炎:谁会从中受益,如何受益?——作者回复
Lancet. 2021 Jul 24;398(10297):300. doi: 10.1016/S0140-6736(21)01422-7.
7
Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study.瑞德西韦和地塞米松治疗的 2019 冠状病毒病(COVID-19)住院患者的生存率提高。一项全国性基于人群的队列研究。
Clin Infect Dis. 2021 Dec 6;73(11):2031-2036. doi: 10.1093/cid/ciab536.
8
Alveolar hemorrhage in the setting of COVID-19: Report of a successful vascular intervention and embolization.新型冠状病毒肺炎背景下的肺泡出血:一例成功的血管介入与栓塞治疗报告
Radiol Case Rep. 2021 Jul;16(7):1777-1779. doi: 10.1016/j.radcr.2021.04.034. Epub 2021 May 4.
9
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效(RECOVERY):一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
10
Tocilizumab in COVID-19: some clarity amid controversy.托珠单抗治疗新冠病毒病:争议中渐趋明晰
Lancet. 2021 May 1;397(10285):1599-1601. doi: 10.1016/S0140-6736(21)00712-1.